

Gender as a Modifying Factor Influencing Myotonic Dystrophy Type 1 Phenotype Severity and Mortality: A Nationwide Multiple Databases Cross-Sectional Observational Study

Celine Dogan, Marie de Antonio, Dalil Hamroun, Hugo Varet, Marianne Fabbro, Felix Rougier, Khadija Amarof, Marie-Christine Arne Bes, Anne-Laure Bedat-Millet, Anthony Behin, et al.

► **To cite this version:**

Celine Dogan, Marie de Antonio, Dalil Hamroun, Hugo Varet, Marianne Fabbro, et al.. Gender as a Modifying Factor Influencing Myotonic Dystrophy Type 1 Phenotype Severity and Mortality: A Nationwide Multiple Databases Cross-Sectional Observational Study. PLoS ONE, Public Library of Science, 2016, 11 (2), pp.e0148264. 10.1371/journal.pone.0148264 . hal-01274908

HAL Id: hal-01274908

<https://hal-univ-rennes1.archives-ouvertes.fr/hal-01274908>

Submitted on 20 Sep 2018

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



RESEARCH ARTICLE

Gender as a Modifying Factor Influencing Myotonic Dystrophy Type 1 Phenotype Severity and Mortality: A Nationwide Multiple Databases Cross-Sectional Observational Study



OPEN ACCESS

Citation: Dogan C, De Antonio M, Hamroun D, Varet H, Fabbro M, Rougier F, et al. (2016) Gender as a Modifying Factor Influencing Myotonic Dystrophy Type 1 Phenotype Severity and Mortality: A Nationwide Multiple Databases Cross-Sectional Observational Study. *PLoS ONE* 11(2): e0148264. doi:10.1371/journal.pone.0148264

Editor: Ruben Artero, University of Valencia, SPAIN

Received: September 22, 2014

Accepted: January 16, 2016

Published: February 5, 2016

Copyright: © 2016 Dogan et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: Data are governed by ethical and legal restrictions. Data are from three databases: DM-Scope registry, whose authors may be contacted at guillaume.bassez@hmn.aphp.fr; the AFM-Téléthon DM1 survey, whose authors may be contacted at alain.geille1@libertysurf.fr; The French National Health Service database, whose authors may be contacted at gilbert.caranhac@hox-com.com.

Funding: The study has been funded by AFM-Téléthon, <http://www.afm-telethon.fr/>, GB. The funders had no role in study design, data collection

Celine Dogan¹, Marie De Antonio^{1,2}, Dalil Hamroun³, Hugo Varet¹, Marianne Fabbro¹, Felix Rougier¹, Khadija Amarof⁴, Marie-Christine Arne Bes⁵, Anne-Laure Bedat-Millet⁶, Anthony Behin⁷, Remi Bellance⁴, Françoise Bouhour⁸, Celia Boutte⁹, François Boyer¹⁰, Emmanuelle Campana-Salort¹¹, Françoise Chapon¹², Pascal Cintas⁵, Claude Desnuelle¹³, Romain Deschamps⁴, Valerie Drouin-Garraud⁶, Xavier Ferrer¹⁴, Helene Gervais-Bernard⁸, Karima Ghorab¹⁵, Pascal Laforet⁷, Armelle Magot¹⁶, Laurent Magy¹⁵, Dominique Menard¹⁷, Marie-Christine Minot¹⁷, Aleksandra Nadaj-Pakleza¹⁸, Sybille Pellioux¹⁹, Yann Pereon¹⁶, Marguerite Preudhomme²⁰, Jean Pouget¹¹, Sabrina Sacconi¹³, Guilhem Sole¹⁴, Tanya Stojkovich⁷, Vincent Tiffreau²⁰, Andoni Urtizberea²¹, Christophe Vial⁸, Fabien Zagnoli²², Gilbert Caranhac²³, Claude Bourlier²⁴, Gerard Riviere²⁴, Alain Geille²⁴, Romain K. Gherardi¹, Bruno Eymard⁷, Jack Puymirat²⁵, Sandrine Katsahian², Guillaume Bassez^{1*}

1 Neuromuscular Reference Center, GH Henri Mondor, AP-HP, Créteil, France, INSERM U955, UPEC university, Créteil, France, **2** INSERM U1138, Centre de recherche des cordeliers, Paris Descartes university, UPMC university, Paris, France, **3** Direction de la Recherche et de l'Innovation, CHU Montpellier, Montpellier, France, **4** Neuromuscular Reference Center, CHU Fort-de-France, Fort de France, France, **5** Neuromuscular Reference Center, CHU Toulouse, Toulouse, France, **6** Neuromuscular Competence Center, CHU Rouen, Rouen, France, **7** Neuromuscular Reference Center, GH Pitié-Salpêtrière, AP-HP, Paris, France, **8** Neuromuscular Reference Center, GH Est, HCL, Bron, France, **9** Neuromuscular Reference Center, CHU Grenoble, Grenoble, France, **10** Neuromuscular Reference Center, CHU Reims, Reims, France, **11** Neuromuscular Reference Center, GH Timone, AP-HM, Marseille, France, **12** Neuromuscular Competence Center, CHU Caen, Caen, France, **13** Neuromuscular Reference Center, CHU Nice, Nice, France, **14** Neuromuscular Reference Center, CHU Bordeaux, Bordeaux, France, **15** Neuromuscular Reference Center, CHU Limoges, Limoges, France, **16** Neuromuscular Reference Center, CHU Nantes, Nantes, France, **17** Neuromuscular Competence Center, CHU Rennes, Rennes, France, **18** Neuromuscular Reference Center, CHU Angers, Angers, France, **19** Neuromuscular Competence Center, CHU Tours, Tours, France, **20** Neuromuscular Reference Center, CHRU Lille, Lille, France, **21** Neuromuscular Reference Center, Hôpital Marin, AP-HP, Hendaye, France, **22** Neuromuscular Competence Center, HIA Clermont-Tonnerre, Brest, France, **23** PMSI Division, Hox-Com Analytiques Paris, France, **24** CoPil, DM1 patients group, AFM-Téléthon, Evry, France, **25** Human Genetic Research Unit, CHU Laval, Quebec, Canada

☉ These authors contributed equally to this work.

* guillaume.bassez@hmn.aphp.fr

Abstract

Background

Myotonic Dystrophy type 1 (DM1) is one of the most heterogeneous hereditary disease in terms of age of onset, clinical manifestations, and severity, challenging both medical

and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

Abbreviations: AFM, "Association Française contre les myopathies"; BMI, Body mass Index; CI, Confidence Interval; DM1, Myotonic Dystrophy type 1; FDM-S, French DM1 patients' survey; FSHD, Facioscapulohumeral Muscular Dystrophy; FVC, Forced Ventilated Capacity; HypoPP, Hypokalemic Periodic Paralysis; ISCED, International Standard Classification of Education; MIRS, Muscular Impairment Rating Scale; MRC, Medical Research Council Scale; PMSI, French National Health Service Database; RR, Risk Ratio; UTR, Untranslated region.

management and clinical trials. The CTG expansion size is the main factor determining the age of onset although no factor can finely predict phenotype and prognosis. Differences between males and females have not been specifically reported. Our aim is to study gender impact on DM1 phenotype and severity.

Methods

We first performed cross-sectional analysis of main multiorgan clinical parameters in 1409 adult DM1 patients (>18y) from the DM-Scope nationwide registry and observed different patterns in males and females. Then, we assessed gender impact on social and economic domains using the AFM-Téléthon DM1 survey (n = 970), and morbidity and mortality using the French National Health Service Database (n = 3301).

Results

Men more frequently had (1) severe muscular disability with marked myotonia, muscle weakness, cardiac, and respiratory involvement; (2) developmental abnormalities with facial dysmorphism and cognitive impairment inferred from low educational levels and work in specialized environments; and (3) lonely life. Alternatively, women more frequently had cataracts, dysphagia, digestive tract dysfunction, incontinence, thyroid disorder and obesity. Most differences were out of proportion to those observed in the general population. Compared to women, males were more affected in their social and economic life. In addition, they were more frequently hospitalized for cardiac problems, and had a higher mortality rate.

Conclusion

Gender is a previously unrecognized factor influencing DM1 clinical profile and severity of the disease, with worse socio-economic consequences of the disease and higher morbidity and mortality in males. Gender should be considered in the design of both stratified medical management and clinical trials.

Introduction

Myotonic dystrophy type 1 (DM1 or Steinert's disease; OMIM 160900) is the most frequent adult muscular dystrophy with a prevalence of about 5/100000 [1, 2]. DM1 clinical manifestations include prominent distal muscle weakness, myotonia and multiorgan involvement mainly affecting the heart, eye, brain, and endocrine system [3]. This autosomal dominant genetic disease is caused by an unstable trinucleotide CTG repeat expansion in the 3' UTR of the DM protein kinase (*DMPK*) gene [4–7]. Unaffected individuals have 5–37 CTG repeats in this gene which remains stable over generations. In DM1, unstable >40 CTG repeats expansion tends to increase among the different tissues and in successive generations accounting for the anticipation phenomenon [8–10]. The CTG expansion length which correlates inversely with the disease age of onset is currently the only known predictor of some phenotypic manifestations. However, modifier gene or epigenetic factors causing conspicuous variability of DM1 multisystemic involvement in a given individual remain poorly understood.

Of note, large collections of DM1 patients are scant in the literature and usually focus on given manifestations, such as cardiac or endocrine symptoms [11–34]. The gender of the transmitting parent is known to affect CTG size in the offspring, causing preferential transmission

of congenital forms by the mother [35–36]. However, gender has not been specifically studied and disease manifestations are considered similar in male and female patients. Here, by a cross-sectional analysis of a large cohort of DM1 patients enrolled in the DM-scope registry and two additional independent nationwide databases we identified the impact of gender on DM1 phenotype’s severity, socio-economic conditions and mortality.

Materials and Methods

Study design

Cross-sectional analysis of the DM-scope registry. We first analysed 1409 French adult DM1 patients (>18yrs) of the DM-scope registry (Fig 1), which collects in a standardized form relevant clinical and epidemiological data during routine medical evaluation performed in French neuromuscular reference centers. Analyses focused on two themes: patients’ genotype/phenotype and socio-economic conditions.

Complementary study in two nationwide systems. We used two other independent national databases (Fig 2) for initial analysis validation and for complementary results (i) the French DM1 patients survey of patients’ health and medical care (FDM-S, n = 970) and (ii) the French National Health Service Database (PMSI—Programme de Médicalisation des Systèmes d’Information, n = 3301) to assess morbidity and mortality. In FDM-S survey, the AFM-Telethon foundation asked DM1 patients (>18yrs) to fulfill questionnaires about their socio-economic status, the main symptoms with their specific impact on the everyday life, medical care and genetic counselling. The PMSI database monitors and harmonizes medical care in hospitals in France. We analysed data collected on French adult DM1 patients (>18yrs) in 2010–2011, with emphasis on history of hospitalizations and death notification. The DM-scope, FDM-S and PMSI databases were approved by the data protection national authority; the DM-scope study was approved by ethics committee and participating patients granted their informed consent. The DM-scope study was approved in 2008 by the CNIL (National Commission on Informatics and Liberty, #1282122). As an information system restricted to standard medical use, no written consent is required by the CNIL and all participating patients received information letter and granted their verbal informed consent. Patient consent is documented in the database and in all centers. This consent procedure has been approved by the




Fig 1. Patient selection of DM-Scope registry.

doi:10.1371/journal.pone.0148264.g001




Fig 2. Design of cross-sectional observational study and respective contribution of three national databases: DM-Scope, FDM-S, PMSI Relevant clinical and epidemiological data from French DM1 adult patients (n = 1409), enrolled in DM-Scope registry, were compared to two complementary independent databases, AFM French DM1 survey of patients health and medical care (FDM-S, n = 970 patients) and the National Health Service Database (PMSI, n = 3301), according to similar criteria (age > 18y, standardized nationwide collection). Analyses focused on gender effect as a modifying factor of DM1 clinical phenotype, socio-economic status, morbidity and mortality.

doi:10.1371/journal.pone.0148264.g002

national ethic committee CCTIRS (Advisory Committee on Information Processing in Material Research in the Field of Health)

Definitions and classification

Clinical manifestations. Muscle strength was measured using the modified-Medical Research Council (MRC) scale [37] evaluating neck flexors, shoulder abductors, elbow flexors and extensors, wrist extensors, finger flexors, hip flexors, knee flexors and extensors, posterior foot flexors, and plantar flexors muscles. Muscle strength of each muscle group was graded utilizing a modified MRC score that was converted to a 11-point scale (from 0 to 10), instead of 6 point scale. We used the validated muscular impairment rating scale (MIRS) to quantify DM1-related motor impairment [38].

We used the educational level based on International Standard Classification of Education (ISCED) for indirect assessment of cognitive performance.

The following definition criteria were used: “severe myotonia”: time to open hands after contraction ≥ 3 sec; “respiratory insufficiency”: forced ventilation capacity (FVC) <70%; “hypoxemia”: $\text{PaO}_2 < 70$ mmHg; “hypercapnia”: $\text{PaCO}_2 > 45$ mmHg “cardiac conduction defects”: ECG showing left hemiblock or bundle branch block; “abnormal ECG”: PR >200ms or QRS >120ms; “somnolence”: Epworth sleepiness scale score >10; “dysphagia”: coughing during eating or drinking more than twice a month and 80 mL-swallowing time test >6 sec [3]; “digestive disorders”: diarrhoea or constipation; “muscle impairment”: muscular impairment rating

Table 1. Characteristics of patients in the DM-scope registry.

	Mean age of patients in yrs (SD)	Mean age of onset (SD)	Mean CTG expansion (SD)	Congenital form in %	Infantile form in %	Juvenile form in %	Adult form in %	Late onset form in %
Female (749)	42.65 (12,8)	24.53 (14)	647.72 (452)	3.59	15.72	25.66	42.21	12.83
Male (660)	42.38 (13.4)	23.72 (15)	628.9 (433)	4.59	17.72	24.68	39.72	13.29
Overall (1409)	42.52 (13)	24.15 (14)	639.1 (443)	4.05	16.65	25.2	41.05	13.04
	NS	NS	NS	NS	NS	NS	NS	NS

doi:10.1371/journal.pone.0148264.t001

scale (MIRS) score >3; “couple’s hypofertility”: delay to get the first child >18 months; “overweight/obesity”: body mass index (BMI) >25.

Clinical classification. There is no consensus clinical classification of DM1. Besides the widely accepted *congenital myotonic dystrophy*, there are various definitions of childhood-onset DM1. Herein, we classified DM1 into five clinical forms according to the age at onset of first clinical manifestation (adapted from [4]): (1) congenital form: neonatal (mild to severe) hypotonia, respiratory distress, sucking or swallowing difficulties, or skeletal deformities detected at birth or during the first month of life; (2) infantile form: clinical onset from 1 month to 10 years; (3) juvenile form: onset at 11–20 years; (4) adult form: onset at 21–40 years; (5) late onset form: onset after 40 years.

Statistical analyses

Cross-sectional analysis of the whole DM-scope registry was carried out using data collected in the last medical appointment, prior to July 2013. Categorical variables were compared using the chi-square or Fisher test. Quantitative variables showing non-Gaussian distribution were compared using the non-parametric Mann-Whitney U test. The means of the CTG repeat expansions were compared by the non-parametric Kruskal Wallis test, with the Dunn post-hoc test. Gender differences for several disease-related features were expressed as the risk ratio (RR) of men/women with 95% confidence interval (CI). RR was statistically significant at alpha = 0.05 when 95% CI boundary values did not overlap value 1. P-values <0.05 were considered significant. Statistical analyses were performed using the using R 3.0.2 software (the R Foundation for Statistical Computing, Vienna, Austria).

Results

Population characteristics

Among the 1409 adult DM1 patients enrolled since 2009 in the DM-Scope registry, a small majority (53.15%) were women, but age, CTG repeats expansion size, age-of-onset, and distribution into the 5 clinical forms were similar between men and women, allowing comparisons of genders in further analyses (Table 1). A strong correlation was found in both men and women between CTG repeat expansion size and the different clinical forms (Fig 3), supporting the robustness of the classification based on the age-of-onset.

Gender of transmitters and severity

As a general rule, repeat expansions were longer in case of maternal inheritance (mean 804 ±507) vs. (600 ±393) in case of paternal transmissions, p<0.0001). Surprisingly, congenital DM1 onset was not exclusively associated with maternal inheritance (91% maternal




Fig 3. CTG repeat expansion size in male and female individuals according to DM1 clinical forms. Analyses assessed robustness of the conventional age of onset-based classification of DM1 with regard to the triplet expansion size. Inside each clinical form, no difference in CTG expansion size was observed between male and female groups. Performed tests: multiple comparison of mean (non parametric Kruskal Wallis test and post hoc test; * $p < 0.05$, ** $p < 0.001$, *** $p < 0.0001$).

doi:10.1371/journal.pone.0148264.g003

inheritance vs 9% paternal inheritance). Infantile forms were equally transmitted by mothers (50%) and fathers (50%) (Table 2). Maternally inherited infantile forms showed longer repeat expansions (1051 (± 401) vs 760 (± 376), $p < 0.0001$). more severe cognitive impairment (ISCED ≤ 3 , $p = 0.01$; specialized educational environment, $p = 0.005$) and developmental abnormalities (facial dysmorphism, $p < 0.05$) than paternally inherited ones. Unexpectedly for an autosomal dominant disorder, juvenile, adult and late onset forms of DM1 were preferentially transmitted by fathers (67, 68 and 63% of paternal transmission, respectively) (Table 2).

Gender of patients and clinical symptoms

The frequency of some symptoms differed, to various extents, between men and women. To illustrate the influence of gender on each symptom, relative risks for men and women were calculated and expressed in form of a forest plot (Fig 4). Men more frequently had developmental abnormalities, severe myotonia, severe cardiac and respiratory involvement and muscle weakness, as assessed by MRC testing ($p = 0.001$). Women had more frequently cataracts, dysphagia, digestive tract dysfunction, incontinence, thyroid disorder and obesity.

By reference to the general French population, DM1 clinical manifestations were ascribed to 3 subgroups: (1) manifestations virtually not encountered in the general population but more

Table 2. Gender effect on disease transmission and CTG expansion.

Parental transmission	Congenital form	Infantile form	Juvenile form	Adult form	Late onset form	Overall
Maternal transmission %	91	50	28	33	32	37
Maternal transmission: mean CTG expansions (SD)	1337 (684)	1051 (401)	784 (369)	617 (393)	294 (310)	804 (507)
Paternal transmission: mean CTG expansions (SD)	1190 (711)	760 (376)	668 (399)	538 (359)	346 (340)	600 (393)
	NS	$p < 0.0001$	$p < 0.05$	NS	NS	$p < 0.0001$

doi:10.1371/journal.pone.0148264.t002




Fig 4. Gender impact on severity of symptoms expressed as risk ratio on 95% confidence interval. This diagram represents the gender relative risk ratio value for each symptom with its 95% confidence interval (segment). A risk ratio is significant if the confidence interval does not cross the vertical line at value 1. The width of confidence interval depends on estimate standard deviation and consequently on observations number.

doi:10.1371/journal.pone.0148264.g004

frequent in a given gender in DM1: facial dysmorphism, myotonia, and delayed conduction at ECG in males; and dysphagia in females; (2) manifestations more frequent in a given gender in the French population but not in the DM1 population (similar frequency in DM1 males and females): higher risk ratio of diabetes in French males [39] was reduced and not significant in both genders in DM1 patients (RR of diabetes in males of the DM1 cohort 1.18 vs. 1.42 in the general population); (3) manifestations more prevalent in a given gender in both the general and DM1 population, with an accentuated gender effect in DM1 for thyroid disorders and obesity (RR of thyroid disorders in females of the DM1 cohort 2.15 vs. 1.12 in the general population; RR of obesity in females of the DM1 cohort 1.58 vs. 1.10 in the general population [40,41]).

Gender of patients and socio-economic conditions

Comparative analyses between men and women revealed also a different impact of DM1 on social and economic conditions. Men more often had lonely life styles (single: 34% in women vs. 60% in men, $p < 0.0001$), low education level (ISCED ≤ 3 : 62 in women vs. 68% in men $p < 0.05$) and work in protected environments (30 vs. 49%, $p < 0.05$). Regarding the marital status, males living alone were found markedly enhanced in DM1 (RR of single status in males of the DM1 cohort is 1.74 vs 1.05 in the general population). Lower educational levels also more prevalent in males was proportionate in the DM1 and general population (RR of ISCED ≤ 3 in males of the DM1 cohort is 1.10 vs 1.16 in the general population [42])

Substantiation of gender impact on DM1 using FDM-S and PMSI databases

The FDM-S survey and the PMSI hospitalization database included 56.4% and 49.8% female DM1 patients, respectively, and this was considered in the analytical methods to limit bias. In

Table 3. Comparison of most disabling symptoms in FDM-S to DM-Scope registry related findings.

FDM-S	Cardiac conduction defects	Respiratory insufficiency	Cataracts	Elocution difficulties	Writing difficulties	Somnolence	Diabetes	Dysphagia
Male	45%	34%	47%	51%	50%	40%	9%	29%
Female	37%	23%	59%	32%	34%	44%	7.2%	25%
	<i>p</i> <0.001	<i>p</i> <0.001	<i>p</i> <0.0001	<i>p</i> <0.0001	<i>p</i> <0.001	NS	NS	NS
DM-Scope	ECG abnormalities	Respiratory insufficiency	Cataracts	Facial dysmorphism	Severe myotonia	Somnolence	Diabetes	Dysphagia
Male	44.4%	40%	58.9%	49%	44%	21.7%	9.4%	44.1%
Female	37.7%	29.5%	67.4%	37%	30%	25.3%	8%	52.1%
	<i>p</i> <0.01	<i>P</i> <0.001	<i>p</i> <0.01	<i>p</i> <0.0001	<i>p</i> <0.0001	NS	NS	<i>p</i> <0.01

doi:10.1371/journal.pone.0148264.t003

the three cohorts, DM1 patients were comparable for mean age (42.5 yrs (±13.1) in DM-Scope vs. 45.5 (±12.1) in FDM-S vs. 47.9 (±14.3) in PMSI). Comparison for CTG repeat expansion was not performed (data not available in FDM-S and PMSI).

In FDM-S (n = 970), men and women showed similar medical compliance, consulting as frequently the main specialists (cardiologist, pneumonologist, neurologist, and psychologist), at the exception of ophthalmologists more often met by women (*p*<0.03). Analysis of the more disabling symptoms reported in FDM-S confirmed gender-dependent differences detected in the DM-scope registry (Table 3). Men presented more frequently cardiac arrhythmia and respiratory insufficiency. Half of them complained of elocution difficulties, facial weakness (*p*<0.0001), and writing difficulties (*p*<0.001) related to either severe myotonia (*p*<0.0001). Women more frequently reported cataracts. According to the DM-scope registry, gender does not affect somnolence or diabetes. However, in FDM-S, women did not complain of dysphagia more often than men.

FDM-S survey also confirmed the impact of gender on socio-economic parameters. It included nearly half of single men (60% in the DM-scope cohort), and bachelorhood was considered as a serious life-impacting problem by 30% of DM1 males. Educational difficulties were attributed to slowness (*p*<0.05) and were more often responsible for educational switch in men (*p*<0.05). Men also experienced career changes more often (*p*<0.05).

PMSI database (n = 3301) analysis revealed gender impact on DM1 morbi-mortality. Hospitalizations of DM1 patients were compared to 11304 hospitalizations of gender groups of similar age during the same 2010–2011 period. DM1 males patients had higher hospitalization rate for cardiac conduction defect (*p* = 0.003) or respiratory insufficiency (*p* = 0.03), whereas women were preferentially admitted for visual difficulties (*p* = 0.001) and endocrine or metabolic dysfunction (*p*<0.0001). Analysis of death declarations indicated a higher mortality rate in men (*p* = 0.009).

Discussion

Our study revealed the multidimensional influence of gender in DM1. First, maternal inheritance was associated with longer repeat expansions and more severe phenotype, as previously reported [5, 6]. This has been attributed to marked DNA instability in the female germ cell lineage allowing additional triplets insertion during oogenesis [43]. Such instability also results to an anticipation in case of maternal inheritance, a phenomenon corresponding to earlier onset and more severe symptoms observed in successive generations [10]. Surprisingly, and in contrast to the general assumptions, we observed that fathers transmitted up to 9% of neonatal onset (mild or severe) forms and 50% of infantile forms, especially those with lower cognitive

impairment. Another unexpected observation was that only a minority of overall DM1 patients (37%) had maternal inheritance, which is most unusual for an autosomal dominant inherited disease. It probably results from increased miscarriage and perinatal lethality observed in female DM1 transmitters.

The second gender difference implied an unequal prevalence of several DM1 signs and symptoms in men and women. These differences could not be accounted for overall quantitative male-to-female disproportion in our study population (considered in all statistical analysis), or for the age and genotype differences between the two groups. Men tended to have more obvious classical DM1 symptoms, combining cognitive impairment, marked myotonia, cardiac and respiratory involvement whereas women had more extra-muscular and late onset manifestations, less suggestive of DM1, such as cataracts, obesity, dysthyroidism, GI symptoms and sphincter dysfunction. The most poorly symptomatic patients were women, implicating occasional hidden DM1 transmissions by undiagnosed female mutation carriers. In practice, the sex-related differential risks of developing specific manifestations may require sex-orientated care management, which should be specifically adapted for men (at higher risk of mechanical ventilation, respiratory failure or cardiac conduction defects, which could provide more frequent hospitalization and increased mortality according PMSI database) as well as for women (at higher risk of dysthyroidism, obesity, sphincter dysfunction, and cataracts). This gender disproportion suggests that women could be more careful with their own health. This is underlined by FDM-S survey showing a similar number of annual routine visits to the cardiologist and pneumonologist for both genders, despite male have more cardiac and respiratory involvement, which should prompt more regular medical care. Altogether, the results highlight the importance of a greater awareness about preventive medical care in DM1 male individuals.

The major strengths of this study include (i) the unprecedented number of patients with genetically confirmed DM1 included in the DM-scope cohort, (ii) the prospective and standardized collection of data in the registry performed by expert physicians, (iii) the single country-based enrolment of patients allowing comparisons with the general population, and (iv) the validation of important results by analysis of two other national DM1 sources (FDM-S, PMSI). Similarly described in the literature, cross sectional studies discussed in our work are inappropriate for the analysis of age-dependant symptoms in a given clinical form. This point deserves a follow-up study using complex *ad hoc* statistical approaches.

The exact mechanisms underlying gender-dependent differences remain unknown. More diffusely severe myopathy in male patients assessed by MRC testing was reminiscent of some other muscular diseases of autosomal inheritance, such as FSHD, hypokalemic periodic paralysis (HypoPP) or ANO5 mutation-related myopathy [44]. It has been experimentally established that both genetic background [45] and male gender may influence the severity of weakness in mouse autosomal muscular dystrophy. Male and female skeletal muscles display considerable differences in their metabolic properties and gene expression patterns [46,47]. In congenital myotonia, sexual steroid hormones influence severity of myotonia, reflecting testosterone modulation of CLCN1 chloride channel activity [48]. In cardiovascular diseases, it has been described a possible early-life sex-dependent vulnerability to oxidative stress [49]. Other gender-related cellular differences can be considered, as recently proposed [50].

Conclusion

In conclusion, the present study identified gender as a previously unrecognized factor influencing DM1 manifestations with sex-related distinctive clinical profiles and severity. Worse socioeconomic consequences of the disease and higher morbidity and mortality were observed in

DM1 males. Gender of DM1 patients should be considered in the design of both stratified medical management and clinical trials.

Acknowledgments

We would like to thank all the patients and the staff members that participated to collect data at every site, particularly: R Auguston, S Brimont, J Bourbon, R Chasserieu, AM Cobo, MC Cruz, F Lebeau, M Macletbourienne, P Poitou. We also thank M Gomes-Pereira and N Thanagarajah who reviewed the manuscript. We are grateful to AFM-Téléthon for its support.

Author Contributions

Conceived and designed the experiments: C. Dogan DH GB BE J. Puymirat. Performed the experiments: C. Dogan MDA SK RKG GB. Analyzed the data: MDA HV FR. Contributed reagents/materials/analysis tools: C. Dogan MDA RKG SK GB BE J. Puymirat. Wrote the paper: C. Dogan MDA RKG SK GB. Collected and monitored DM-Scope data: MF KA MCA ALB AB RB F. Bouhour C. Boutte F. Boyer ECS FC PC C. Desnuelle RD VDG XF HGB KG PL AM LM DM MCM ANP SP YP MP J. Pouget SS GS TS VT AU CV FZ. Managed DM1 patients Survey (FDM-S): C. Bourlier GR AG. Managed PMSI database: GC.

References

1. Pinessi L, Bergamini L, Cantello R, Di Tizio C. Myotonia congenita and myotonic dystrophy: descriptive epidemiological investigation in Turin. *Ital J Neurol Sci*. 1982 Oct; 3(3):207–10. PMID: [7161034](#)
2. Mathieu J, De Braekeleer M, Prevost C. Genealogical reconstruction of myotonic dystrophy in the Saguenay-Lac-Saint-Jean area (Quebec, Canada). *Neurology*. 1990 May; 40(5):839–42. PMID: [2330114](#)
3. Harper P. Myotonic Dystrophy, 3rd Edition-Major Problems in Neurology. In: *Medicine*; 2001.
4. Aslanidis C, Jansen G, Amemiya C, Shuttler G, Mahadevan M, Tsilfidis C et al. Cloning of the essential myotonic dystrophy region and mapping of the putative defect. *Nature*. 1992 Feb 6; 355(6360):548–51. PMID: [1346925](#)
5. Brook JD, McCurrach ME, Harley HG, Buckler AJ, Church D, Aburatani H et al. Molecular basis of myotonic dystrophy: expansion of a trinucleotide (CTG) repeat at the 3' end of a transcript encoding a protein kinase family member. *Cell*. 1992 Feb 21; 68(4):799–808. PMID: [1310900](#)
6. Fu YH, Pizzuti A, Fenwick RG Jr, King J, Rajnarayan S, Dunne PW et al. An unstable triplet repeat in a gene related to myotonic muscular dystrophy. *Science*. 1992 Mar 6; 255(5049):1256–8. PMID: [1546326](#)
7. Mahadevan M, Tsilfidis C, Sabourin L, Shuttler G, Amemiya C, Jansen G et al. Myotonic dystrophy mutation: an unstable CTG repeat in the 3' untranslated region of the gene. *Science*. 1992 Mar 6; 255(5049):1253–5. PMID: [1546325](#)
8. Harley HG, Brook JD, Rundle SA, Crow S, Reardon W, Buckler AJ et al. Expansion of an unstable DNA region and phenotypic variation in myotonic dystrophy. *Nature*. 1992 Feb 6; 355(6360):545–6. PMID: [1346923](#)
9. Hunter A, Tsilfidis C, Mettler G, Jacob P, Mahadevan M, Surh L et al. The correlation of age of onset with CTG trinucleotide repeat amplification in myotonic dystrophy. *J Med Genet*. 1992 Nov; 29(11):774–9. PMID: [1453425](#)
10. Harper PS, Harley HG, Reardon W, Shaw DJ (1992) Anticipation in myotonic dystrophy: new light on an old problem. *Am J Hum Genet*. 1992 Jul; 51(1):10–6. PMID: [1609789](#)
11. Novelli G, Gennarelli M, Menegazzo E, Mostacciolo ML, Pizzuti A, Fattorini C et al. (CTG)_n triplet mutation and phenotype manifestations in myotonic dystrophy patients. *Biochem Med Metab Biol*. 1993 Aug; 50(1):85–92. PMID: [8373638](#)
12. Mastrogiacomo I, Pagani E, Novelli G, Angelini C, Gennarelli M, Menegazzo E et al. Male hypogonadism in myotonic dystrophy is related to (CTG)_n triplet mutation. *J Endocrinol Invest*. 1994 May; 17(5):381–3. PMID: [8077624](#)
13. Damian MS, Bachmann G, Koch MC, Schilling G, Stoppler S, Dorndorf W. Brain disease and molecular analysis in myotonic dystrophy. *Neuroreport*. 1994 Dec 20; 5(18):2549–52. PMID: [7696601](#)

14. Eguchi I, Koike R, Onodera O, Tanaka K, Kondo H, Tsuji S. Correlation between degrees of the CTG repeat expansion and clinical features of myotonic dystrophy. *Rinsho Shinkeigaku*. 1994 Feb; 34(2):118–23. PMID: [8194263](#)
15. Jaspert A, Fahsold R, Grehl H, Claus D. Myotonic dystrophy: correlation of clinical symptoms with the size of the CTG trinucleotide repeat. *J Neurol*. 1995 Jan; 242(2):99–104. PMID: [7707098](#)
16. Gennarelli M., Novelli G, Andreasi Bassi F, Martorell L, Cornet M, Menegazzo E, et al. Prediction of myotonic dystrophy clinical severity based on the number of intragenic [CTG]_n trinucleotide repeats. *Am J Med Genet*. 1996 Nov 11; 65(4):342–7. PMID: [8923947](#)
17. Martorell L, Johnson K, Boucher CA, Baiget M. Somatic instability of the myotonic dystrophy (CTG)_n repeat during human fetal development. *Hum Mol Genet*. 1997 Jun; 6(6):877–80. PMID: [9175733](#)
18. Utsugisawa K, Yamagata M, Nagane Y, Tohgi H. Effects of CTG repeat expansion on quantitative muscle histopathology in myotonic dystrophy. *Nihon Rinsho*. 1997 Dec; 55(12):3214–8. Review. PMID: [9436439](#)
19. Gharehbaghi-Schnell EB, Finsterer J, Korschineck I, Mamoli B, Binder BR. Genotype-phenotype correlation in myotonic dystrophy. *Clin Genet*. 1998 Jan; 53(1):20–6. PMID: [9550357](#)
20. Hsiao KM, Chen SS, Li SY, Chiang SY, Lin HM, Pan H et al. Epidemiological and genetic studies of myotonic dystrophy type 1 in Taiwan. *Neuroepidemiology*. 2003 Sep-Oct; 22(5):283–9. PMID: [12902623](#)
21. Osanai R, Kinoshita M, Hirose K. Eye movement disorders in myotonic dystrophy type 1. *Acta Otolaryngol Suppl*. 2007 Dec;(559:):78–84. doi: [10.1080/03655230701597192](#) PMID: [18340575](#)
22. Finsterer J, Stollberger C, Blazek G, Kunafer M, Prager E. Cardiac involvement over 10 years in myotonic and Becker muscular dystrophy and mitochondrial disorder. *Int J Cardiol*. 2007 Jul 10; 119(2):176–84. Epub 2007 Jan 25. PMID: [17258336](#)
23. Kuo HC, Hsieh YC, Wang HM, Chuang WL, Huang CC. Correlation among subcortical white matter lesions, intelligence and CTG repeat expansion in classic myotonic dystrophy type 1. *Acta Neurol Scand*. 2008 Feb; 117(2):101–7. doi: [10.1111/j.1600-0404.2007.00911.x](#) PMID: [18184345](#)
24. Hermans MC, Faber CG, Vanhoutte EK, Bakkers M, De Baets MH, de Die-Smulders CE et al. Peripheral neuropathy in myotonic dystrophy type 1. *J Peripher Nerv Syst*. 2011 Mar; 16(1):24–9. doi: [10.1111/j.1529-8027.2011.00313.x](#) PMID: [21504499](#)
25. Groh WJ, Groh MR, Shen C, Monckton DG, Bodkin CL, Pascuzzi RM. Survival and CTG repeat expansion in adults with myotonic dystrophy type 1. *Muscle Nerve*. 2011 May; 43(5):648–51. doi: [10.1002/mus.21934](#) PMID: [21484823](#)
26. Kaminsky P, Poussel M, Pruna L, Deibener J, Chenuel B, Brembilla-Perrot B. Organ dysfunction and muscular disability in myotonic dystrophy type 1. *Medicine (Baltimore)*. 2011 Jul; 90(4):262–8. doi: [10.1097/MD.0b013e318226046b](#)
27. Marchini C, Lonigro R, Verriello L, Pellizzari L, Bergonzi P, Damante G. Correlations between individual clinical manifestations and CTG repeat amplification in myotonic dystrophy. *Clin Genet*. 2000 Jan; 57(1):74–82. PMID: [10733240](#)
28. Perini GI, Menegazzo E, Ermani M, Zara M, Gemma A, Ferruzza E, et al., Cognitive impairment and (CTG)_n expansion in myotonic dystrophy patients. *Biol Psychiatry*. 1999 Aug 1; 46(3):425–31. PMID: [10435210](#)
29. Marcon M, Briani C, Ermani M, Menegazzo E, Iurilli V, Feltrin GP et al. Positive correlation of CTG expansion and pharyngoesophageal alterations in myotonic dystrophy patients. *Ital J Neurol Sci*. 1998 Apr; 19(2):75–80. PMID: [10935840](#)
30. Garcia-Gomez T, Maestre J, Garrido ML, Vilches R, Fernandez MD, Mínguez A et al. Genotype-phenotype correlation in myotonic dystrophy and prediction of clinical seriousness. *Rev Neurol*. 1999 Sep 16–30; 29(6):499–502. Spanish. PMID: [10584260](#)
31. Morales F, Couto JM, Higham CF, Hogg G, Cuenca P, Braida C et al. Somatic instability of the expanded CTG triplet repeat in myotonic dystrophy type 1 is a heritable quantitative trait and modifier of disease severity. *Hum Mol Genet*. 2012 Aug 15; 21(16):3558–67. doi: [10.1093/hmg/dds185](#) Epub 2012 May 16. PMID: [22595968](#)
32. Higham CF, Morales F, Cobbold CA, Haydon DT, Monckton DG. High levels of somatic DNA diversity at the myotonic dystrophy type 1 locus are driven by ultra-frequent expansion and contraction mutations. *Hum Mol Genet*. 2012 Jun 1; 21(11):2450–63. doi: [10.1093/hmg/dds059](#) Epub 2012 Feb 24. PMID: [22367968](#)
33. Brais B, Xie YG, Sanson M, Morgan K, Weissenbach J, Korczyn AD et al. The oculopharyngeal muscular dystrophy locus maps to the region of the cardiac alpha and beta myosin heavy chain genes on chromosome 14q11.2-q13. *Hum Mol Genet*. 1995 Mar; 4(3):429–34. PMID: [7795598](#)

34. Koch MC, Grimm T, Harley HG, Harper PS. Genetic risks for children of women with myotonic dystrophy. *Am J Hum Genet.* 1991 Jun; 48(6):1084–91. PMID: [2035529](#)
35. Ashizawa T, Dubel JR, Dunne PW, Dunne CJ, Fu YH, Pizzuti A et al. Anticipation in myotonic dystrophy. II. Complex relationships between clinical findings and structure of the GCT repeat. *Neurology.* 1992 Oct; 42(10):1877–83. PMID: [1407566](#)
36. Lavedan C, Hofmann-Radvanyi H, Shelbourne P, Rabes JP, Duros C, Savoy D et al. Myotonic dystrophy: size- and sex-dependent dynamics of CTG meiotic instability, and somatic mosaicism. *Am J Hum Genet.* 1993 May; 52(5):875–83. PMID: [8098180](#)
37. Muscle Study Group. Randomised pilot trial of beta1NF-1a in patients with inclusion body myositis. *Neurology.* 2001 Nov 13; 57(9):1566–70. Erratum in: *Neurology* 2002 Jan 22;58(2):334. PMID: [11706093](#)
38. Mathieu J, Boivin H, Meunier D, Gaudreault M, Begin P. Assessment of a disease-specific muscular impairment rating scale in myotonic dystrophy. *Neurology.* 2001 Feb 13; 56(3):336–40. PMID: [11171898](#)
39. Fagot-Campagna A, Romon I, Fosse S, Roudier C. Prévalence et incidence du diabète, et mortalité liée au diabète en France. Available: http://www.invs.sante.fr/publications/2010/plaquette_diabete/plaquette_diabete.pdf.
40. Estaquio C, Valeix P, et al. Maladies thyroïdiennes dans la cohorte SU.VI.MAX. Available: http://www.invs.sante.fr/publications/2009/maladies_thyroidiennes_suvimax/maladies_thyroidiennes_suvimax.pdf
41. Eschwege E, Charles MA, Basdevant A, Moisan, C, Bonnelye G et al, (2012) Enquête épidémiologique nationale sur le surpoids et l'obésité. Available: http://www.roche.fr/content/dam/corporate/roche_fr/doc/obepi_2012.pdf
42. Sociodemographic data. Available: http://www.insee.fr/fr/themes/detail.asp?reg_id=0&ref_id=bilan-demo&page=donnees-detaillees/bilan-demo/pop_age2b.htm; http://www.insee.fr/fr/themes/detail.asp?reg_id=99&ref_id=pop-17ans-dipl; http://www.insee.fr/fr/themes/tableau.asp?reg_id=0&ref_id=NATCCF07235
43. Dean NL, Tan SL, Ao A. Instability in the transmission of the myotonic dystrophy CTG repeat in human oocytes and preimplantation embryos. *Fertil Steril.* 2006 Jul; 86(1):98–105. Epub 2006 May 23. PMID: [16716318](#)
44. Ke Q, Luo B, Qi M, Du Y, Wu W. Gender differences in penetrance and phenotype in hypokalemic periodic paralysis. *Muscle Nerve.* 2013 Jan; 47(1):41–5. doi: [10.1002/mus.23460](#) Epub 2012 Sep 27. PMID: [23019082](#)
45. Heydemann A, Swaggart KA, Kim GH, Holley-Cuthrell J, Hadhazy M, McNally EM. The superhealing MRL background improves muscular dystrophy. *Skelet Muscle.* 2012 Dec 5; 2(1):26. doi: [10.1186/2044-5040-2-26](#) PMID: [23216833](#)
46. Green HJ, Fraser IG, Ranney DA. Male and female differences in enzyme activities of energy metabolism in vastus lateralis muscle. *J Neurol Sci.* 1984 Sep; 65(3):323–31. PMID: [6238135](#)
47. Welle S, Tawil R, Thornton CA. Sex-related differences in gene expression in human skeletal muscle. *PLoS One.* 2008 Jan 2; 3(1):e1385. doi: [10.1371/journal.pone.0001385](#) PMID: [18167544](#)
48. Fialho D, Kullmann DM, Hanna MG, Schorge S. Non-genomic effects of sex hormones on CLC-1 may contribute to gender differences in myotonia congenita. *Neuromuscul Disord.* 2008 Nov; 18(11):869–72. doi: [10.1016/j.nmd.2008.07.004](#) Epub 2008 Sep 23. PMID: [18815035](#)
49. Minghetti L, Greco A, Zanardo V, Suppiej A. Early-life sex-dependent vulnerability to oxidative stress: the natural twinning model. *J Matern Fetal Neonatal Med.* 2013 Feb; 26(3):259–62. doi: [10.3109/14767058.2012.733751](#) Epub 2012 Oct 19. PMID: [23020682](#)
50. Straface E, Gambardella L, Brandani M, Malorni W. Sex differences at cellular level: "cells have a sex". *Handb Exp Pharmacol.* 2012;(214):49–65. doi: [10.1007/978-3-642-30726-3_3](#) Review. PMID: [23027445](#)